Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type

European Journal of Dermatology

Volumn 20, Issue 6, 2010, Pages 753-757

  Fenot, Marion ^a   Quereux, Gaelle ^a   Brocard, Anabelle ^a   Renaut, Jean Jacques ^a   Dreno, Brigitte ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse event; Chemotherapy; Cutaneous lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRURITUS; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; LOWER EXTREMITY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78649882719     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.1102     Document Type: Article

References (24)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
2. Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19: 3602-10. (Pubitemid 32786274)
3. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112: 1600-9.
4. Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006; 24: 1376-82.
5. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol 2005; 153: 874-80.
6. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-79.
7. Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143: 1144-50.
8. Grange F, Maubec E, Bagot M, Beylot-Barry M, Joly P, Dalle S, et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol 2009; 145: 329-30.
9. Posada Garcia C, Florez A, Pardavila R, Garcia-Cruz A, Amador L, Alvarez M, et al. Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy. Eur J Dermatol 2009; 19: 394-5.
10. Guyot A, Ortonne N, Valeyrie-Allanore L, Bagot M. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients. Arch Dermatol 2010; 146: 89-91.
11. Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol 2008; 59: 953-7.
12. Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-44.
13. Sabroe RA, Child FJ, Woolford AJ, Spittle MF, Russell-Jones R. Rituximab in cutaneous B-cell lymphoma: a report of two cases. Br J Dermatol 2000; 143: 157-61. (Pubitemid 30485261)
14. Aboulafia DM. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Am J Clin Oncol 2001; 24: 237-40.
15. Garbea A, Dippel E, Hildenbrand R, Bleyl U, Schadendorf D, Goerdt S. Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol 2002; 146: 144-7. (Pubitemid 34158426)
16. Bonnekoh B, Schulz M, Franke I, Gollnick H. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. J Cancer Res Clin Oncol 2002; 128: 161-6. (Pubitemid 34185639)
17. Viguier M, Bachelez H, Brice P, Rivet J, Dubertret L. Cutaneous B-cell lymphoma treatment with rituximab: two cases. Ann Dermatol Venereol 2002; 129: 1152-5. (Pubitemid 35315301)
18. Zinzani PL, Stefoni V, Alinari L, Vianelli N, Baccarani M. Rituximab in heavily pretreated cutaneous B-cell lymphoma. Leuk Lymphoma 2003; 44: 1637-8. (Pubitemid 36833985)
19. Brogan BL, Zic JA, Kinney MC, Hu JY, Hamilton KS, Greer JP. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series. J Am Acad Dermatol 2003; 49: 223-8.
20. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. Br J Dermatol 2005; 153: 167-73. (Pubitemid 41044544)
21. Lacouture ME, Baron JM, Jani AB, Laumann AE, Soltani K. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Clin Exp Dermatol 2005; 30: 46-8. (Pubitemid 40188318)
22. Pedraz J, Delgado Y, Ballestero M, Fraga J, Garcia-Diez A, Fernandez-Herrera J. Cutaneous large B-cell lymphoma of the leg. Actas Dermosifiliogr 2005; 96: 237-40. (Pubitemid 40868450)
23. Dreno B. Standard and new treatments in cutaneous B-cell lymphomas. J Cutan Pathol 2006; 33 (Suppl 1): 47-51.
24. Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel B, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009; 20: 326-30.